|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: IGHM |
Gene summary for IGHM |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | IGHM | Gene ID | 3507 |
| Gene name | immunoglobulin heavy constant mu | |
| Gene Alias | AGM1 | |
| Cytomap | 14q32.33 | |
| Gene Type | other | GO ID | GO:0001775 | UniProtAcc | NA |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 3507 | IGHM | GSM4909290 | Human | Breast | IDC | 4.37e-52 | 8.48e-01 | 0.2096 |
| 3507 | IGHM | GSM4909317 | Human | Breast | IDC | 5.65e-05 | 1.64e-01 | 0.1355 |
| 3507 | IGHM | M1 | Human | Breast | IDC | 7.45e-23 | 6.18e-01 | 0.1577 |
| 3507 | IGHM | P4T-E | Human | Esophagus | ESCC | 3.03e-10 | 1.08e-01 | 0.1323 |
| 3507 | IGHM | P5T-E | Human | Esophagus | ESCC | 1.07e-08 | 3.52e-02 | 0.1327 |
| 3507 | IGHM | P10T-E | Human | Esophagus | ESCC | 7.83e-13 | -1.02e-02 | 0.116 |
| 3507 | IGHM | P20T-E | Human | Esophagus | ESCC | 3.01e-11 | 1.70e-01 | 0.1124 |
| 3507 | IGHM | P26T-E | Human | Esophagus | ESCC | 6.14e-37 | 7.21e-01 | 0.1276 |
| 3507 | IGHM | P28T-E | Human | Esophagus | ESCC | 1.14e-24 | 3.85e-01 | 0.1149 |
| 3507 | IGHM | P31T-E | Human | Esophagus | ESCC | 1.45e-09 | 3.37e-02 | 0.1251 |
| 3507 | IGHM | P32T-E | Human | Esophagus | ESCC | 3.32e-19 | 1.97e-01 | 0.1666 |
| 3507 | IGHM | P37T-E | Human | Esophagus | ESCC | 1.41e-20 | 4.16e-01 | 0.1371 |
| 3507 | IGHM | P39T-E | Human | Esophagus | ESCC | 6.38e-12 | 3.84e-02 | 0.0894 |
| 3507 | IGHM | P42T-E | Human | Esophagus | ESCC | 9.41e-19 | 2.44e-01 | 0.1175 |
| 3507 | IGHM | P44T-E | Human | Esophagus | ESCC | 5.02e-04 | 8.53e-02 | 0.1096 |
| 3507 | IGHM | P47T-E | Human | Esophagus | ESCC | 1.05e-15 | -9.57e-02 | 0.1067 |
| 3507 | IGHM | P52T-E | Human | Esophagus | ESCC | 1.26e-09 | 3.28e-02 | 0.1555 |
| 3507 | IGHM | P54T-E | Human | Esophagus | ESCC | 4.05e-06 | -2.76e-02 | 0.0975 |
| 3507 | IGHM | P62T-E | Human | Esophagus | ESCC | 1.43e-12 | 6.25e-02 | 0.1302 |
| 3507 | IGHM | P74T-E | Human | Esophagus | ESCC | 1.64e-02 | 1.14e-01 | 0.1479 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001973011 | Breast | IDC | antimicrobial humoral response | 23/1434 | 122/18723 | 4.67e-05 | 1.04e-03 | 23 |
| GO:00069596 | Breast | IDC | humoral immune response | 40/1434 | 317/18723 | 1.25e-03 | 1.33e-02 | 40 |
| GO:00512515 | Breast | IDC | positive regulation of lymphocyte activation | 43/1434 | 362/18723 | 2.72e-03 | 2.41e-02 | 43 |
| GO:00022532 | Breast | IDC | activation of immune response | 43/1434 | 375/18723 | 5.16e-03 | 3.84e-02 | 43 |
| GO:00026966 | Breast | IDC | positive regulation of leukocyte activation | 46/1434 | 409/18723 | 5.60e-03 | 4.07e-02 | 46 |
| GO:00323926 | Esophagus | HGIN | DNA geometric change | 25/2587 | 90/18723 | 3.77e-04 | 5.85e-03 | 25 |
| GO:00325084 | Esophagus | HGIN | DNA duplex unwinding | 22/2587 | 84/18723 | 1.91e-03 | 2.03e-02 | 22 |
| GO:00062604 | Esophagus | ESCC | DNA replication | 181/8552 | 260/18723 | 3.55e-15 | 2.05e-13 | 181 |
| GO:003239214 | Esophagus | ESCC | DNA geometric change | 62/8552 | 90/18723 | 7.02e-06 | 7.04e-05 | 62 |
| GO:003250813 | Esophagus | ESCC | DNA duplex unwinding | 58/8552 | 84/18723 | 1.23e-05 | 1.14e-04 | 58 |
| GO:00063101 | Esophagus | ESCC | DNA recombination | 168/8552 | 305/18723 | 5.58e-04 | 3.05e-03 | 168 |
| GO:00062603 | Oral cavity | OSCC | DNA replication | 159/7305 | 260/18723 | 3.25e-13 | 1.59e-11 | 159 |
| GO:00323925 | Oral cavity | OSCC | DNA geometric change | 59/7305 | 90/18723 | 3.03e-07 | 4.63e-06 | 59 |
| GO:00325083 | Oral cavity | OSCC | DNA duplex unwinding | 55/7305 | 84/18723 | 8.05e-07 | 1.12e-05 | 55 |
| GO:0006310 | Oral cavity | OSCC | DNA recombination | 147/7305 | 305/18723 | 6.33e-04 | 3.56e-03 | 147 |
| GO:00027646 | Oral cavity | OSCC | immune response-regulating signaling pathway | 212/7305 | 468/18723 | 2.93e-03 | 1.27e-02 | 212 |
| GO:000276413 | Oral cavity | EOLP | immune response-regulating signaling pathway | 108/2218 | 468/18723 | 4.04e-12 | 7.34e-10 | 108 |
| GO:00027683 | Oral cavity | EOLP | immune response-regulating cell surface receptor signaling pathway | 66/2218 | 315/18723 | 2.44e-06 | 5.45e-05 | 66 |
| GO:00512517 | Oral cavity | EOLP | positive regulation of lymphocyte activation | 72/2218 | 362/18723 | 6.21e-06 | 1.22e-04 | 72 |
| GO:00024292 | Oral cavity | EOLP | immune response-activating cell surface receptor signaling pathway | 60/2218 | 291/18723 | 1.16e-05 | 2.00e-04 | 60 |
| Page: 1 2 3 4 5 6 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| IGHM | SNV | Missense_Mutation | novel | c.254A>T | p.His85Leu | p.H85L | IG_C_gene | tolerated(0.35) | unknown(0) | TCGA-B6-A0IN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| IGHM | SNV | Missense_Mutation | novel | c.337N>A | p.Val113Met | p.V113M | IG_C_gene | tolerated(0.14) | unknown(0) | TCGA-D8-A1XL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide+tamoxifen | SD | |
| IGHM | insertion | Frame_Shift_Ins | novel | c.82_83insCCCAAAGTGAGCGTCTTCGTCCC | p.Cys28SerfsTer41 | p.C28Sfs*41 | IG_C_gene | TCGA-A2-A0D1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD | |||
| IGHM | SNV | Missense_Mutation | novel | c.851N>T | p.Ala284Val | p.A284V | IG_C_gene | tolerated(0.79) | possibly_damaging(0.691) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| IGHM | SNV | Missense_Mutation | novel | c.122N>T | p.Ser41Phe | p.S41F | IG_C_gene | deleterious(0) | unknown(0) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| IGHM | SNV | Missense_Mutation | rs372720307 | c.1172N>A | p.Arg391Gln | p.R391Q | IG_C_gene | tolerated(0.27) | benign(0.412) | TCGA-EA-A50E-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD | |
| IGHM | SNV | Missense_Mutation | rs372261472 | c.76G>A | p.Val26Ile | p.V26I | IG_C_gene | tolerated(0.65) | unknown(0) | TCGA-FU-A5XV-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD | |
| IGHM | SNV | Missense_Mutation | novel | c.346T>C | p.Phe116Leu | p.F116L | IG_C_gene | tolerated(0.18) | unknown(0) | TCGA-AA-3492-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| IGHM | SNV | Missense_Mutation | rs375873260 | c.905C>T | p.Thr302Met | p.T302M | IG_C_gene | tolerated(0.07) | possibly_damaging(0.895) | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| IGHM | SNV | Missense_Mutation | rs782615938 | c.853N>A | p.Val285Met | p.V285M | IG_C_gene | tolerated(0.12) | possibly_damaging(0.788) | TCGA-AA-3673-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |